Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 19/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860932 | 1.00 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL18664463 | 1.00 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL487610 | 0.88 | SSTR4 (0.49) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL6039537 | 0.85 | SSTR4 (0.49) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL5634966 | 0.84 | SSTR4 (0.48) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL26668539 | 0.83 | SSTR4 (0.48) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL4967939 | 0.83 | SSTR4 (0.48) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL25023253 | 0.83 | GNAI3 (0.54) | SSTR4 | |
| SCHEMBL25021727 | 0.83 | GNAI3 (0.54) | SSTR4 | |
| SCHEMBL1993031 | 0.82 | SSTR4 (0.53) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079039-A1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | SSTR4 1749/4885CTSC 2854/4885SSTR1 2397/4885 |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | SSTR4 1749/4885CTSC 2854/4885SSTR1 2397/4885 |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | SSTR4 1749/4885CTSC 2854/4885SSTR1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.